Erdheim–Chester disease and vemurafenib: a review of ophthalmic presentations and clinical outcomes

References

• Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020;135(16):1311–1318. doi:10.1182/blood.2019002766.
   PubMed Web of Science ®Google Scholar
• Estrada-Veras JI, O’-Brien KJ, Boyd LC, Dave RH, Durham BH, Xi L, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357–366. doi:10.1182/bloodadvances.2016001784.
   PubMed Web of Science ®Google Scholar
• Cives M, Simone V, Rizzo FM, Dicuonzo F, Lacalamita MC, Ingravallo G, et al. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol. 2015;95(1):1–11. doi:10.1016/j.critrevonc.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–492. doi:10.1182/blood-2014-03-561381.
   PubMed Web of Science ®Google Scholar
• Huang LC, Topping KL, Gratzinger D, Brown RA, Martin BA, Silva RA, et al. Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib. Am J Ophthalmol Case Rep. 2018;11:158–163. doi:10.1016/j.ajoc.2018.07.005.
   PubMedGoogle Scholar
• Pichi F. Choroidal mass as the first presentation of Erdheim-Chester disease. Am J Ophthalmol Case Rep. 2019;16:100539. doi:10.1016/j.ajoc.2019.100539.
   PubMedGoogle Scholar
• Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn JE, Wechsler B, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–2782. doi:10.1182/blood-2010-06-294108.
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaih A, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 2017;18(2):e113–e125. doi:10.1016/S1470-2045(17)30031-1.
   PubMed Web of Science ®Google Scholar
• Oneal PA, Kwitkowski V, Luo L, Shen YL, Subramaniam S, Shord S, et al. FDA approval summary: vemurafenib for the treatment of patients with Erdheim‐Chester disease with the BRAF-V600 mutation. Oncologist. 2018;23(12):1520. doi:10.1634/theoncologist.2018-0295.
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–1500. doi:10.1182/blood-2012-07-446286.
   PubMed Web of Science ®Google Scholar
• Grumbine FL, Aderman C, Vagefi MR, Kersten RC. Orbital MRI pre-and post-vemurafenib therapy for Erdheim–Chester disease. Ophthalmic Plast Reconstr Surg. 2015;31(6):e169. doi:10.1097/IOP.0000000000000401.
   PubMed Web of Science ®Google Scholar
• Cohen-Aubart F, Emile JF, Maksud P, Galanaud D, Idbaih A, Chauvet D, et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology. 2014;83(14):1294–1296. doi:10.1212/WNL.0000000000000832.
   PubMed Web of Science ®Google Scholar
• Chester W. Über lipoidgranulomatose. Virchows Arch Pathol Anat Physiol Klin Med. 1930;279(2):561–602. doi:10.1007/BF01942684.
   Google Scholar
• Tan AC, Yzer S, Atebara N, Marr BP, Verdijk RM, Dalm VA, et al. Three cases of Erdheim-Chester disease with intraocular manifestations: imaging and histopathology findings of a rare entity. Am J Ophthalmol. 2017;176:141–147. doi:10.1016/j.ajo.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Biccas LN, Zanetti F. Intraocular involvement in Erdheim-Chester disease–first report in the literature: case report. Arq Bras Oftalmol. 2007;70(5):862–867. doi:10.1590/s0004-27492007000500025.
   PubMedGoogle Scholar
• Abdellatief A, Mason CM, Ytterberg SR, Boorjian SA, Salomão DR, Pulido J. Choroidal involvement in Erdheim-Chester disease. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):674–676. doi:10.3928/23258160-20150610-13.
   PubMed Web of Science ®Google Scholar
• Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye. 2000;14(4):606–612. doi:10.1038/eye.2000.151.
   PubMed Web of Science ®Google Scholar
• Naftaliev E, Leibovitch I, Goldstein-Schwarz M, Kesler A Choroidal and optic nerve involvement in Erdheim-Chester disease. Poster presented at: North American Neuro-Ophthalmology Society Annual Meeting; February 5-10, 2011; Vancouver, BC.
   Google Scholar
• Pineles SL, Liu GT, Acebes X, Arruga J, Nasta S, Glaser R, et al. Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J Neuroophthalmol. 2011;31(3):217–223. doi:10.1097/WNO.0b013e31820a204e.
   PubMed Web of Science ®Google Scholar
• Xiao W, Ye H, Ji X, Yang H. Erdheim‐Chester disease with bilateral choroidal infiltration. Clin Exp Ophthalmol. 2020;48(2):260–262. doi:10.1111/ceo.13665.
   PubMed Web of Science ®Google Scholar
• Chu T. Histiocytosis syndromes in children. Lancet. 1987;1:208–209.
   PubMedGoogle Scholar
• Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681. doi:10.1182/blood-2016-01-690636.
   PubMed Web of Science ®Google Scholar
• Haroun F, Millado K, Tabbara I. Erdheim–Chester disease: comprehensive review of molecular profiling and therapeutic advances. Anticancer Res. 2017;37(6):2777–2783. doi:10.21873/anticanres.11629.
   PubMed Web of Science ®Google Scholar
• Pegoraro F, Papo M, Maniscalco V, Charlotte F, Haroche J, Vaglio A. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia. 2020;34(11):2840–2857. doi:10.1038/s41375-020-0944-4.
   PubMed Web of Science ®Google Scholar
• Prince HM. Identifying mutant pathways in thehistiocytoses. Blood. 2014;124(19):2901–2903. doi:10.1182/blood-2014-09-597765.
   PubMed Web of Science ®Google Scholar
• Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax. 2017;72(10):937–945. doi:10.1136/thoraxjnl-2017-210125.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119. doi:10.1517/14728222.2011.645805.
   PubMed Web of Science ®Google Scholar
• Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124(19):3016–3019. doi:10.1182/blood-2014-04-570937.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013 Aug 8;122(6):1089–1091. doi:10.1182/blood-2013-02-482984.
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, Von Deimling A, Hélias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–2703. doi:10.1182/blood-2012-05-430140.
   PubMed Web of Science ®Google Scholar
• Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013;8(1):137. doi:10.1186/1750-1172-8-137.
   PubMed Web of Science ®Google Scholar
• Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR, et al. The histopathology of Erdheim–Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2018;31(4):581–597. doi:10.1038/modpathol.2017.160.
   PubMed Web of Science ®Google Scholar
• Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, et al. Sirolimus plus prednisone for Erdheim–Chester disease: an open-label trial. Blood. 2015;126:1163–1171. doi:10.1182/blood-2015-01-620377.
   PubMed Web of Science ®Google Scholar
• Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88(6):844–847. doi:10.1136/bjo.2003.035584.
   PubMed Web of Science ®Google Scholar
• Abdellateef EE, Abdelhai AR, Gawish HH, Abdulmonaem GA, Abdelbary EH, Ahmed AI. The first reported case of Erdheim-Chester disease in Egypt with bilateral exophthalmos, loss of vision, and multi-organ involvement in a young woman. Am J Case Rep. 2016;17:360. doi:10.12659/AJCR.897479.
   PubMedGoogle Scholar
• Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med. 2001;135(9):844–845. doi:10.7326/0003-4819-135-9-200111060-00027.
   PubMed Web of Science ®Google Scholar
• Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. Blood. 2010;116(20):4070–4076. doi:10.1182/blood-2010-04-279240.
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta–positive Erdheim-Chester histiocytosis. Blood. 2008;111(11):5413–5415. doi:10.1182/blood-2008-03-148304.
   PubMed Web of Science ®Google Scholar
• Berti A, Cavalli G, Guglielmi B, Biavasco R, Campochiaro C, Tomelleri A, et al. Tocilizumab in patients with multisystem Erdheim–Chester disease. Oncoimmunology. 2017;6(6):e1318237. doi:10.1080/2162402X.2017.1318237.
   PubMed Web of Science ®Google Scholar
• Nordmann TM, Juengling FD, Recher M, Berger CT, Kalbermatten D, Wicki A, et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. Blood. 2017;129(7):879–882. doi:10.1182/blood-2016-09-740217.
   PubMed Web of Science ®Google Scholar
• Fernández-Eulate G, Muñoz-Lopetegi A, Ruiz I, Urtasun M. Vemurafenib as first-line therapy in BRAF -V600E-mutant Erdheim-Chester disease with CNS involvement. BMJ Case Rep. 2019;12(11):e228280. doi:10.1136/bcr-2018-228280.
   PubMedGoogle Scholar
• Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600–mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384–388. doi:10.1001/jamaoncol.2017.5029.
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Mesquida M, Adan A. Uveitic macular oedema after treatment with vemurafenib. Acta Ophthalmol. 2015;93(8):e686–7. doi:10.1111/aos.12678.
   PubMed Web of Science ®Google Scholar
• Wolf SE, Meenken C, Moll AC, Haanen JB, van der Heijden MS. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer. 2013;13(1):561. doi:10.1186/1471-2407-13-561.
   PubMed Web of Science ®Google Scholar
• Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158(4):831–837. doi:10.1016/j.ajo.2014.07.003.
   PubMed Web of Science ®Google Scholar
• Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, et al. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res. 2014;74(8):2238–2245. doi:10.1158/0008-5472.CAN-13-1065-T.
   PubMed Web of Science ®Google Scholar
• Vázquez-Osorio I, Sánchez-Aguilar MD, García-Rodiño S, Suárez-Peñaranda JM, Aliste C, Vázquez-Veiga H. Vemurafenib-Induced neutrophilic panniculitis: a new case and review of the literature. Am J Dermatopathol. 2016;38(7):e93–6. doi:10.1097/DAD.0000000000000528.
   PubMed Web of Science ®Google Scholar
• Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75(3):157–169. doi:10.1097/00005792-199605000-00005.
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N, Cacoub P, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 2004;83(6):371–392. doi:10.1097/01.md.0000145368.17934.91.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Ahmadi A, Tang R, Schiffman J, Kurzrock R. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol. 2001 ;132(6):945–947. doi:10.1016/S0002-9394(01)01141-2.
   PubMed Web of Science ®Google Scholar
• Lau WW, Chan E, Chan CW. Orbital involvement in Erdheim-Chester disease. Hong Kong Med J. 2007;13:238–240.
   PubMedGoogle Scholar
• Valmaggia C, Neuweiler J, Fretz C, Gottlob I. A case of Erdheim-Chester disease with orbital involvement. Arch Ophthalmol. 1997;115(11):1467–1468. doi:10.1001/archopht.1997.01100160637021.
   PubMedGoogle Scholar
• Merritt H, Pfeiffer ML, Richani K, Phillips ME. Erdheim-Chester disease with orbital involvement: Case report and ophthalmic literature review. Orbit. 2016;35(4):221–226. doi:10.1080/01676830.2016.1176211.
   PubMed Web of Science ®Google Scholar
• Shields JA, Karcioglu ZA, Shields CL, Eagle RC, Wong S. Orbital and eyelid involvement with Erdheim-Chester disease. A report of two cases. Arch Ophthalmol. 1991;109(6):850–854. doi:10.1001/archopht.1991.01080060114037.
   PubMedGoogle Scholar
• Hoffmann EM, Müller-Forell W, Pitz S, Radner H. Erdheim-Chester disease: a case report. Graefes Arch Clin Exp Ophthalmol. 2004;242(9):803–807. doi:10.1007/s00417-004-0928-5.
   PubMed Web of Science ®Google Scholar
• Alper MG, Zimmerman LE, Piana FG. Orbital manifestations of Erdheim-Chester disease. Trans Am Ophthalmol Soc. 1983;81:64–85.
   PubMedGoogle Scholar
• de Palma P, Ravalli L, Grisanti F, Rossi A, Marzola A, Nielsen I. Bilateral orbital involvement in Erdheim-Chester disease. Orbit. 1998;17(2):97–105. doi:10.1076/orbi.17.2.97.2758.
   PubMedGoogle Scholar
• Amrith S, Hong Low C, Cheah E, Oo Tan Y. Erdheim-Chester disease: a bilateral orbital mass as an indication of systemic disease. Orbit. 1999;18(2):99–104. doi:10.1076/orbi.18.2.99.2714.
   PubMedGoogle Scholar
• Karcioglu ZA, Sharara N, Boles TL, Nasr AM. Orbital xanthogranuloma: clinical and morphologic features in eight patients. Ophthalmic Plast Reconstr Surg. 2003;19(5):372–381. doi:10.1097/01.IOP.0000083642.15174.83.
   PubMed Web of Science ®Google Scholar
• Cruz AA, de Alencar VM, Falcão MF, J E Jr, Chahud F. Association between Erdheim-Chester disease, Hashimoto thyroiditis, and familial thrombocytopenia. Ophthalmic Plast Reconstr Surg. 2006;22(1):60–62. doi:10.1097/01.iop.0000197021.98742.09.
   PubMed Web of Science ®Google Scholar
• Arora A, Sharma S, Pushker N, Kashyap S, Bakhshi S. Unusual orbital involvement in Erdheim Chester disease: a radiological diagnosis. Orbit. 2012;31(5):338–340. doi:10.3109/01676830.2012.678917.
   PubMedGoogle Scholar
• Oliveira M, Monteiro S, Dos Santos J, Silva AC, Morais Ferreira R. Erdheim-Chester disease: a rare clinical entity. Eur J Case Rep Intern Med. 2020;7:001630.
   PubMedGoogle Scholar
• Gupta A, Yeganeh A, Rootman D, Goldberg R. Vemurafenib (BRAF inhibitor) therapy for orbital erdheim-Chester disease. Ophthalmic Plast Reconstr Surg. 2017;33(6):e138–e139. doi:10.1097/IOP.0000000000000866.
   PubMed Web of Science ®Google Scholar
• Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005 Nov 1;106(9):2992–2994. doi:10.1182/blood-2005-06-2238.
   PubMed Web of Science ®Google Scholar
• Sivak-Callcott JA, Rootman J, Rasmussen SL, Nugent RA, White VA, Paridaens D, et al. Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. Br J Ophthalmol. 2006;90(5):602–608. doi:10.1136/bjo.2005.085894.
   PubMed Web of Science ®Google Scholar
• Rozenberg I, Wechsler J, Koenig F, Brun B, Larde D, Raulo Y, et al. Erdheim-Chester disease presenting as malignant exophthalmos. Br J Radiol. 1986;59(698):173–177. doi:10.1259/0007-1285-59-698-173.
   PubMed Web of Science ®Google Scholar
• Babu RP, Lansen TA, Chadburn A, Kasoff SS. Erdheim-Chester disease of the central nervous system. Report of two cases. J Neurosurg. 1997;86(5):888–892. doi:10.3171/jns.1997.86.5.0888.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Ramey N Long-Term response of Oculofacial Erdheim-Chester disease to vemurafenib. Poster presented at: American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS); Oct 25-26, 2018; Chicago, Illinois.
   Google Scholar
• Aggarwal S, Jakobiec FA, Hamrah P. Bilateral adult epibulbar xanthogranulomas suspicious for Erdheim-Chester disease. Cornea. 2014;33(10):1113–1117. doi:10.1097/ICO.0000000000000191.
   PubMed Web of Science ®Google Scholar
• Brodie J, Zhou S, Makkuni D, Beadsmoore C, Mukhtyar C, Saada J, et al. Erdheim-Chester disease: two cases from an ophthalmic perspective. Am J Ophthalmol Case Rep. 2020;20:100984.
   PubMedGoogle Scholar